OGEN
Oragenics Inc.Recent alerts on OGEN
All signals →
News
Oragenics delays 2023 Annual Meeting - Investing.com
14d ago
SEC filing
OGEN Signs LOI to License CardioDialysis™ for TBI, Targets $3.25M Share Issuance, 3% Royalty, Dual-Barrier Strategy
26d ago
SEC filing
OGEN Doses First Patient in Phase IIa ONP-002 Trial for Concussion, Mackay Hospital Activated March 31, 2026, 40-Patient Study, $9B Global Concussion Market, Intranasal Delivery, CEO Janet Huffman, Dr. James Kelly, HREC Approval, Targets Q4 2026 IND Submission
50d ago
Scanner
Unusual buy pressure (3.5x avg, 68% up-volume, +9.8% / +0.08 intraday, above VWAP)
88d ago
News
Orix Corp Ads Q3 Earnings Call Highlights
113d ago
News
Clinical Trial Demonstrates Accurate Non-Invasive Detection of In Vivo Biologic Activity in Melanomas by the Orlucent® Skin Fluorescent Imaging System
133d ago
News
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
139d ago
News
Bowman Acquires Sierra Overhead Analytics, Expands Technology-enabled Engineering Services
153d ago
SEC filing
OGEN Raises CEO Janet Huffman Salary 5% to $341K, Grants 250K Stock Options
169d ago
Get push alerts for OGEN
Add it to your watchlist in the app and receive every signal the moment it fires.
Download for iOS